PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2
Phase 1/2Active 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Respiratory Papillomatosis
Conditions
Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae
Trial Timeline
Mar 16, 2021 → Jun 5, 2026
NCT ID
NCT04724980About PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 is a phase 1/2 stage product being developed by Precigen for Recurrent Respiratory Papillomatosis. The current trial status is active. This product is registered under clinical trial identifier NCT04724980. Target conditions include Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04724980 | Phase 1/2 | Active |
Competing Products
20 competing products in Recurrent Respiratory Papillomatosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KPL-914 | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| KPL-387 | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Rilonacept + Placebo | Kiniksa Pharmaceuticals | Phase 3 | 72 |
| Enzastaurin (LY317615) + Carboplatin | Eli Lilly | Phase 1 | 33 |
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 80 |
| [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab | Perspective Therapeutics | Phase 1/2 | 33 |
| Ramucirumab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| Gemcitabine and UFTE chemotherapy | Yuhan | Phase 2 | 52 |
| Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab | Daiichi Sankyo | Phase 1/2 | 41 |
| Ifinatamab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| Trastuzumab Deruxtecan | Daiichi Sankyo | Phase 1 | 33 |
| PLX3397 | Daiichi Sankyo | Phase 2 | 52 |
| erlotinib + etoposide | Astellas Pharma | Phase 2 | 52 |
| Drug Combination Therapy | Sun Pharmaceutical | Phase 2 | 52 |
| Niraparib + Anlotinib | Sun Pharmaceutical | Phase 2 | 52 |
| Eribulin Mesylate | Eisai | Pre-clinical | 23 |
| Lenvatinib + Everolimus | Eisai | Phase 1/2 | 41 |
| E7090 | Eisai | Phase 2 | 52 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Eribulin mesilate + Irinotecan hydrochloride | Eisai | Phase 1/2 | 41 |